Sotagliflozin
Type 1 Diabetes
Key Facts
About Lexicon Pharmaceuticals
Lexicon Pharmaceuticals has successfully transitioned from a discovery-focused research organization to a commercial-stage biopharma company following the FDA approval of INPEFA® for heart failure in May 2023. Its core strategy is built upon a systematic, genetics-driven discovery platform that validates novel drug targets in vivo, aiming to de-risk development and deliver first-in-class therapeutics. The company's mission is to address significant unmet medical needs, with current efforts centered on commercializing INPEFA and advancing late-stage candidates like LX9211 for neuropathic pain. Lexicon's future hinges on executing its commercial launch, expanding INPEFA's label, and translating its unique platform into additional high-value clinical assets.
View full company profileTherapeutic Areas
Other Type 1 Diabetes Drugs
| Drug | Company | Phase |
|---|---|---|
| eRapa | Biodexa Pharmaceuticals | Preclinical |
| ImmCelz™ | Creative Medical Technology Holdings | Clinical Trial |
| Adimune (ADi-001/002) | Aditxt | Preclinical / Early Clinical |
| BioChaperone® Lispro (THDB0206) | Adocia | Phase 3 |
| AdoShell® Islet Cell Therapy | Adocia | Preclinical |
| Undisclosed Novel Strategy | CG Scientific | Pre-clinical |
| Stem Cell-Derived Beta Cells | BioTalentum | Pre-clinical |
| NICHE | Continuity Biosciences | Pre-clinical |
| Type I Diabetes | Genclis | Discovery |
| Inreda AP® | Inreda Diabetic | Commercial |
| iTOL-101 | iTolerance | Preclinical |
| iTOL-102 | iTolerance | Preclinical |